NASDAQ: ASTH · Medical Care Facilities
Astrana Health (ASTH) fair value and price range
As of 14 Nov 2026, Faircurve's model values Astrana Health (ASTH) at $38.40 a share. The stock last closed at $32.87, which puts the model's fair value 16.8% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. Astrana Health, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $41.51 to $38.40 (-7.5%). The multiple the model anchors on moved, lowering the fair value: most of the move.
What the model makes of itThe price of $32.87 is 16.8% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 1 Mar 2027. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give ASTH?
The calibrated range for ASTH over 63 trading days is $30.71 to $45.62. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $28.88 to $49.92. In 70% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Astrana Health, Inc. is a healthcare management firm based in Alhambra, California. It was founded in 1985 and rebranded from Apollo Medical Holdings, Inc. in February 2024.
Faircurve's model gives Astrana Health a fair value of $38.40 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $41.51, so the fair value moved -7.5%. In the model's own words, "The multiple the model anchors on moved, lowering the fair value: most of the move." The calibrated range over 63 trading days is $30.71 to $45.62. It is built from the fair value, since there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon, based on 13,250 past valuations. The model grades the evidence behind this valuation as low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
Faircurve's model gives Astrana Health an overall quality score of 66 out of 100 against comparable companies. Three factors stand out. Growth quality scores 95, with trailing revenue growth of 56.4% against a peer median of -2.1%. Earnings quality scores 90, with free cash flow to net income of 3.08x. Balance sheet scores 29, with net debt to EBITDA of 2.71x. The model compares the company with U.S. Physical Therapy, Inc., Healthcare Services Group, Inc., Addus HomeCare Corporation and Hims & Hers Health, Inc., each of which has its own fair value on the site.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does ASTH report earnings, and how has the stock reacted?
Astrana Health's next earnings report is scheduled for 1 Mar 2027. Companies can move their dates.
Around its last 2 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ASTH's last 8 reports, ignoring direction, was 20.8%.
Earlier reports are left out: the options record is on a different share basis.
What the options market has priced for a month's move in ASTH
How does ASTH score on business quality?
Astrana Health's overall quality score is 66 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 34 | 6.7%ROIC | |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 90 | 3.08xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 95 | 56.4%Revenue growth, trailing | -2.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 80 | 1.5%Net buybacks / market value | 0.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 29 | 2.71xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 78 | 2.1 ptsEBITDA margin downside volatility, 5y | 7.0 pts |
How does ASTH compare with similar companies?
The companies in medical care facilities closest to Astrana Health in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| USPH U.S. Physical Therapy, Inc. | $99.55 | $92.36 | -7.2% | Fairly valued |
| HCSG Healthcare Services Group, Inc. | $24.86 | $24.39 | -1.9% | Fairly valued |
| AMN AMN Healthcare Services, Inc. | $39.64 | $43.14 | +8.8% | Low evidence grade |
| ADUS Addus HomeCare Corporation | $124.61 | $133.49 | +7.1% | Fairly valued |
| MD Pediatrix Medical Group, Inc. | $31.89 | $35.38 | +10.9% | Low evidence grade |
| NHC National HealthCare Corporation | $207.19 | $249.00 | +20.2% | Low evidence grade |
| ACHC Acadia Healthcare Company, Inc. | $38.70 | $44.44 | +14.8% | Low evidence grade |
| HIMS Hims & Hers Health, Inc. | $18.56 | $21.46 | +15.6% | Undervalued |
What the comparable companies' multiples alone would give for ASTH, the peer-implied price, is $118.40 a share on this run. The fair value weighs that against the company's own multiple.
All medical care facilities stocks ranked by gap to fair value
Astrana Health at a glance
Astrana Health, Inc., which rebranded from Apollo Medical Holdings, Inc. in February 2024, is a healthcare management firm based in Alhambra, California, founded in 1985.
- Market value
- $1.6B
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Revenue expected, next twelve months
- $4.3B
- Consensus revenue growth, next fiscal year
- +24.9%
- Analysts with estimates
- 5
- Beta to the US market
- 0.60
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Astrana Health on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for ASTH was $41.51. As of 14 Nov 2026 it is $38.40, a change of -7.5%. The multiple the model anchors on moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Astrana Health's valuation
Is Astrana Health stock undervalued or overvalued?
Faircurve's model puts ASTH's fair value at $38.40 a share against a last close of $32.87, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is ASTH's fair value?
$38.40 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $28.88 to $49.92.
What price range does the model give ASTH?
$30.71 to $45.62 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does Astrana Health report earnings next?
The next report is scheduled for 1 Mar 2027. Companies can move their dates.
How much has ASTH moved on past earnings reports?
Across its last 8 reports the median two session move was 20.8%, ignoring direction. The largest was +28.7% around the report of 7 Aug 2025.
How confident is the model in this valuation?
The model's evidence grade for ASTH is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on ASTH
The model holds no idea open on ASTH today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ASTH with their outcomes. A free account is enough.